Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.

ABSTRACT: BACKGROUND:This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia. METHODS:Type 2 diabetic patients (56) with microalbuminuria and hypertriglyceridemia aged 30 to 75 were randomly divided into the fenofibrate treatment group(n?=?28) and the control group (n?=?28) for 180?days. Urinary microalbumin /creatinine ratio (UACR) and other metabolic parameters were compared at baseline, during treatment and after treatment. RESULTS:After 180?days, the reduction of level of fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) between two groups showed no difference. In the treatment group, uric acid (UA) (296.42?±?56.41 vs 372.46?±?72.78), triglyceride (TG) [1.51(1.17, 2.06) vs 3.04(2.21, 3.29)], and UACR [36.45 (15.78,102.41) vs 129.00 (53.00, 226.25)] were significantly decreased compared with the baseline. The high-density lipoprotein cholesterol (HDL-C) levels were significantly increased (1.22?±?0.26 vs 1.09?±?0.24) compared with the baseline. The decrease in UACR [-?44.05(-?179.47, -?12.16) vs -?8.15(-?59.69, 41.94)]in treatment group was significantly higher compared with the control group. The decrease in UACR was positively associated with the decreases in TG (r?=?0.447, P?=?0.042) and UA (r?=?0.478, P?=?0.024) after fenofibrate treatment. CONCLUSION:In the patients with hypertriglyceridemia and type 2 diabetes mellitus, fenofibrate can improve microalbuminuria and do not increase the deterioration of glomerular filtration rate. TRIAL REGISTRATION:ClinicalTrials.gov identifier: NCT02314533, 2014.12.9.

SUBMITTER: Sun X 

PROVIDER: S-EPMC7245839 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature